AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19265745 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm plus placebo gel hydroxyethyl cellulose (HEC)
Number of subjects: 192
Study 19265745 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidform alone
Number of subjects: 192
Study 19265745 — intervention group
Group type: EXPERIMENTAL
Intervention: HEC alone
Number of subjects: 192
Study 19265745 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel-diaphragm users
Number of subjects: 192
Study 19265745 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel-only users
Number of subjects: 192
Study 17479444 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined T3/T4 therapy
Number of subjects: 20
Study 17479444 — intervention group
Group type: COMPARATOR
Intervention: T4 alone
Number of subjects: 20
Study 15207442 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity for 3 viruses (herpes simplex type 1, herpes simplex type 2, cytomegalovirus)
Number of subjects: 383
Study 15207442 — intervention group
Group type: COMPARATOR
Intervention: Viral burden (0-1, 2, and 3 positive titers)
Number of subjects: 383
Study 15207442 — intervention group
Group type: COMPARATOR
Intervention: 2 seropositivities
Number of subjects: 383
Study 15207442 — intervention group
Group type: COMPARATOR
Intervention: 3 seropositivities
Number of subjects: 383
Study 15207442 — intervention group
Group type: COMPARATOR
Intervention: Baseline MMSE score
Number of subjects: 383
Study 11742168 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type-A (Botox) injection - 10 units to each side of the puborectalis or 20 units to the posterior aspect of this muscle.
Number of subjects: 25
Study 11742168 — intervention group
Group type: EXPERIMENTAL
Intervention: Further injections of Botox (1-5 every 3 months) for those who did not respond to the first injection.
Number of subjects: 25
Study 9537613 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron glycine (1.4 mg added Fe/serving)
Number of subjects: 9
Study 9537613 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (1.4 mg added Fe/serving)
Number of subjects: 9
Study 8018689 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 weekly sessions on nutrition and behavior modification
Number of subjects: 39
Study 8018689 — intervention group
Group type: COMPARATOR
Intervention: Lecture and brief video on diet and cholesterol
Number of subjects: 39
Study 2574549 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 36
Study 2574549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 917713 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending to the stimulus material
Number of subjects: 111
Study 917713 — intervention group
Group type: COMPARATOR
Intervention: Attending to the interval of passing time
Number of subjects: 111
Study 917713 — intervention group
Group type: COMPARATOR
Intervention: Three different interval conditions
Number of subjects: 111
Study 31591130 — intervention group
Group type: EXPERIMENTAL
Intervention: NTM-1634 at 0.33 mg/kg
Number of subjects: 24
Study 31591130 — intervention group
Group type: EXPERIMENTAL
Intervention: NTM-1634 at 0.66 mg/kg
Number of subjects: 24
Study 31591130 — intervention group
Group type: EXPERIMENTAL
Intervention: NTM-1634 at 1 mg/kg
Number of subjects: 24
Study 31591130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28383362 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 0
Study 28383362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26012700 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based prostate cancer treatment decision aid (DA) offered after diagnosis.
Number of subjects: 19
Study 26012700 — intervention group
Group type: COMPARATOR
Intervention: Usual information and decisional support (Control group).
Number of subjects: 19
Study 24687643 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad-based briefing (EB)
Number of subjects: 101
Study 24687643 — intervention group
Group type: COMPARATOR
Intervention: Classic written briefing
Number of subjects: 101
Study 22754476 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-body skin examination by a clinician with presumptive diagnosis (abnormal finding, no abnormal finding)
Number of subjects: 312
Study 22754476 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up care as advised
Number of subjects: 312
Study 22754476 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and cognitive variables
Number of subjects: 312
Study 18177867 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/day letrozole
Number of subjects: 64
Study 18177867 — intervention group
Group type: COMPARATOR
Intervention: 150 mg/day clomiphene citrate (CC)
Number of subjects: 64
Study 17209177 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D supplement (600 mg elemental calcium and 200 IU vitamin D/tablet, 2 tablets/d)
Number of subjects: 63
Study 17209177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 17209177 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D supplement
Number of subjects: 63
Study 14987190 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise therapy programme
Number of subjects: 132
Study 14987190 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 132
Study 11193224 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity (LI) strength training, n = 9 participants
Number of subjects: 27
Study 11193224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) strength training, n = 9 participants
Number of subjects: 27
Study 11193224 — intervention group
Group type: COMPARATOR
Intervention: Control group, n = 9 participants
Number of subjects: 27
Study 9134445 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) for four months
Number of subjects: 39
Study 9134445 — intervention group
Group type: COMPARATOR
Intervention: Cognitive‐based stress education control (SEC) for four months
Number of subjects: 39
Study 8205276 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 0
Study 8205276 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 0
Study 8205276 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study 3229875 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 28
Study 3229875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30049691 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurements using standard mercury sphygmomanometers
Number of subjects: 60025
Study 27500660 — intervention group
Group type: EXPERIMENTAL
Intervention: Termination of pregnancy (TOP)
Number of subjects: 742
Study 26168681 — intervention group
Group type: EXPERIMENTAL
Intervention: Rengalin (2 tablets 3 times daily for 3 days, then half dose for 4 days)
Number of subjects: 143
Study 26168681 — intervention group
Group type: COMPARATOR
Intervention: Codelac (1 tablet 3 times daily for 7 days)
Number of subjects: 143
Study 26168681 — intervention group
Group type: EXPERIMENTAL
Intervention: Rengalin
Number of subjects: 143
Study 23254595 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-sodium, high-potassium salt substitute (65% sodium chloride, 25% potassium chloride, 10% magnesium sulfate)
Number of subjects: 462
Study 23254595 — intervention group
Group type: COMPARATOR
Intervention: Normal salt (100% sodium chloride)
Number of subjects: 462
Study 21910897 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic cholecystectomy (SPLC)
Number of subjects: 110
Study 21910897 — intervention group
Group type: COMPARATOR
Intervention: 4-port conventional laparoscopic cholecystectomy (4PLC)
Number of subjects: 110
Study 21910897 — intervention group
Group type: EXPERIMENTAL
Intervention: SPLC
Number of subjects: 110
Study 21910897 — intervention group
Group type: EXPERIMENTAL
Intervention: SPLC and 4PLC
Number of subjects: 110
Study 18381567 — intervention group
Group type: EXPERIMENTAL
Intervention: MC-1, 250 mg/d
Number of subjects: 3023
Study 18381567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3023
Study 18381567 — intervention group
Group type: EXPERIMENTAL
Intervention: MC-1
Number of subjects: 3023
Study 17064600 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG (CCABG)
Number of subjects: 79
Study 17064600 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG (OPCAB)
Number of subjects: 79
Study 17064600 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CCABG and OPCAB)
Number of subjects: 79
Study 12747229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 10 mg of dexamethasone phosphate in two doses at an interval of 12 hours
Number of subjects: 66
Study 15163329 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg MMI
Number of subjects: 30
Study 15163329 — intervention group
Group type: COMPARATOR
Intervention: 150 mg PTU
Number of subjects: 30
Study 9922408 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-oxygen mixture (heliox)
Number of subjects: 205
Study 9922408 — intervention group
Group type: COMPARATOR
Intervention: Oxygen alone
Number of subjects: 205
Study 8549882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletid (1.5 micrograms/kg body weight)
Number of subjects: 60
Study 8549882 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study 2109658 — intervention group
Group type: EXPERIMENTAL
Intervention: L-deprenyl (10 mg/day)
Number of subjects: 20
Study 2109658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 346153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (antifibrinolytic agent) for six weeks after rupture of an intracranial aneurysm
Number of subjects: 50
Study 346153 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antifibrinolytic treatment)
Number of subjects: 50
Study 31304912 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic-analgesic ear drops
Number of subjects: 106
Study 31304912 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106
Study 31304912 — intervention group
Group type: COMPARATOR
Intervention: Placebo ear drops
Number of subjects: 106
Study 31304912 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drops (three-group study)
Number of subjects: 106
Study 31304912 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic analysis of NHS costs for active drops
Number of subjects: 106
Study 31304912 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 106
Study 28229980 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with oral iron supplementation
Number of subjects: 60
Study 28229980 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation with acupuncture
Number of subjects: 60
Study 28229980 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 28229980 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture combined with oral iron supplementation
Number of subjects: 60
Study 25855340 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide 0.6 mg
Number of subjects: 45
Study 25855340 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide 1.2 mg
Number of subjects: 45
Study 25855340 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide 1.8 mg
Number of subjects: 45
Study 25855340 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 45
Study 23807360 — intervention group
Group type: EXPERIMENTAL
Intervention: Human RV vaccine (RIX4414)
Number of subjects: 148
Study 23807360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 21849007 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (SITA) 100 mg qd
Number of subjects: 492
Study 21849007 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (PIO) 15 mg qd (up-titrated to 30 mg after 6 weeks)
Number of subjects: 492
Study 21849007 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin (SITA/MET) (up-titrated to 50/1000 mg bid over 4 weeks)
Number of subjects: 492
Study 21849007 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (PIO) (up-titrated to 45 mg qd)
Number of subjects: 492
Study 19892280 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.50%
Number of subjects: 81
Study 19892280 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.75%
Number of subjects: 81
Study 19892280 — intervention group
Group type: COMPARATOR
Intervention: Control (1100 ppm F, NaF)
Number of subjects: 81
Study 16860258 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d
Number of subjects: 5924
Study 16860258 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d
Number of subjects: 5924
Study 16860258 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d
Number of subjects: 5924
Study 16860258 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 5924
Study 16860258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5924
Study 15005812 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium-based supplement (1 tablespoon with 8 oz of water, twice daily for 4 days)
Number of subjects: 0
Study 15005812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11355932 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking P‐glycoprotein‐mediated drug efflux
Number of subjects: 0
Study 11355932 — intervention group
Group type: COMPARATOR
Intervention: MDR1, MRP1 and LRP expression
Number of subjects: 0
Study 9160925 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg ipratropium bromide
Number of subjects: 0
Study 9160925 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microg ipratropium bromide
Number of subjects: 0
Study 7714551 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNU 75-100 mg/m2 IV every 8 weeks
Number of subjects: 152
Study 7714551 — intervention group
Group type: COMPARATOR
Intervention: AZQ 15 mg/m2 IV once a week for 4 weeks, every 6-8 weeks
Number of subjects: 152
Study 30241126 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy
Number of subjects: 1
Study 27921414 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous serum therapy
Number of subjects: 50
Study 27921414 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study 23914845 — intervention group
Group type: EXPERIMENTAL
Intervention: Concussed subjects
Number of subjects: 0
Study 23914845 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 24353020 — intervention group
Group type: EXPERIMENTAL
Intervention: Red morphine drops (RMD) - 1/12 of their 24-hour morphine dose
Number of subjects: 20
Study 24353020 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine (SCM) - 60 percent of their 24-hour morphine dose
Number of subjects: 20
Study 20950405 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 51
Study 20950405 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 51
Study 17645558 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG/GLIM FDC regimen A (4 mg/4 mg OD maximal)
Number of subjects: 901
Study 17645558 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG/GLIM FDC regimen B (8 mg/4 mg OD maximal)
Number of subjects: 901
Study 17645558 — intervention group
Group type: COMPARATOR
Intervention: RSG (8 mg OD maximal)
Number of subjects: 901
Study 17645558 — intervention group
Group type: COMPARATOR
Intervention: GLIM (4 mg OD maximal)
Number of subjects: 901
Study 17645558 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG/GLIM FDC regimen A
Number of subjects: 901
Study 17645558 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG/GLIM FDC regimen B
Number of subjects: 901
Study 17645558 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG/GLIM FDC
Number of subjects: 901
Study 16710084 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐IC bypass surgery
Number of subjects: 10
Study 16710084 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 10
Study 12800456 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doxazosin
Number of subjects: 1705
Study 12800456 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS formulation
Number of subjects: 1705
Study 11203858 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink Low (Vivadent; n = 18)
Number of subjects: 16
Study 11203858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric (n = 21; Vivadent)
Number of subjects: 16
Study 8841156 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin therapeutic drug monitoring (TDM) group (n = 37)
Number of subjects: 70
Study 8841156 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 70
Study 8841156 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin therapeutic drug monitoring (TDM)
Number of subjects: 70
Study 1478400 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (4 mg)
Number of subjects: 40
Study 1478400 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg) followed by Molsidomine (4 mg)
Number of subjects: 40
Study 1478400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1478400 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 40
Study 2858145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.01 mg/kg and Vecuronium 0.005 mg/kg
Number of subjects: 24
Study 2858145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.01 mg/kg and Vecuronium 0.01 mg/kg
Number of subjects: 24
Study 2858145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.01 mg/kg and Vecuronium 0.015 mg/kg
Number of subjects: 24
Study 29571083 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) chemotherapy
Number of subjects: 195
Study 29571083 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 195
Study 25909598 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic (fructo-oligosaccharide, FOS)
Number of subjects: 18
Study 25909598 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 18
Study 25909598 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (FOS+Lactobacillus and Bifidobacteria strains)
Number of subjects: 18
Study 25132158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (50 mg.kg(‐1) followed by a continuous infusion of 15 mg.kg(‐1) .h(‐1))
Number of subjects: 44
Study 25132158 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (same volume as magnesium group)
Number of subjects: 44
Study 25132158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 44
Study 22584952 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 g of chocolate containing 80% cacao
Number of subjects: 26
Study 22584952 — intervention group
Group type: COMPARATOR
Intervention: Cacao-free white chocolate (placebo)
Number of subjects: 26
Study 20432513 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Tension (AT) technique
Number of subjects: 614
Study 20432513 — intervention group
Group type: COMPARATOR
Intervention: No treatment (donation-as-usual condition)
Number of subjects: 614
Study 18584274 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on colonoscopy performance
Number of subjects: 581
Study 18584274 — intervention group
Group type: COMPARATOR
Intervention: No feedback on colonoscopy performance
Number of subjects: 581
Study 16133430 — intervention group
Group type: COMPARATOR
Intervention: Healthy voluntary subjects
Number of subjects: 0
Study 16133430 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with swallowing disorders
Number of subjects: 0
Study 16133430 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with tracheal tubes or cannulae
Number of subjects: 0
Study 12182385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine (HbOC)
Number of subjects: 0
Study 12182385 — intervention group
Group type: COMPARATOR
Intervention: Control group (children excluded from the trial)
Number of subjects: 0
Study 10201676 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 340
Study 10201676 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 340
Study 10201676 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 340
Study 10201676 — intervention group
Group type: COMPARATOR
Intervention: 2% mepivacaine
Number of subjects: 340
Study 7801861 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol 10 g and lovastatin 20 mg/day (C10 + L20)
Number of subjects: 96
Study 7801861 — intervention group
Group type: COMPARATOR
Intervention: Colestipol 5 g and lovastatin 20 mg/day (C5 + L20)
Number of subjects: 96
Study 7801861 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin 40 mg/day (L40)
Number of subjects: 96
Study 7801861 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 96
Study 7801861 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combinations
Number of subjects: 96
Study 2139940 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem-cilastatin 500 mg 8-hourly
Number of subjects: 211
Study 2139940 — intervention group
Group type: COMPARATOR
Intervention: cefotaxime 1 g 6-hourly combined with amikacin 5 mg/kg 8-hourly
Number of subjects: 211
Study 378733 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine 100 mg
Number of subjects: 70
Study 378733 — intervention group
Group type: COMPARATOR
Intervention: Phenylpropanolamine 50 mg
Number of subjects: 70
Study 378733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31247584 — intervention group
Group type: EXPERIMENTAL
Intervention: V-K group (focused first on visual information, then on kinesthetic information)
Number of subjects: 30
Study 31247584 — intervention group
Group type: EXPERIMENTAL
Intervention: K-V group (focused first on kinesthetic information, then on visual information)
Number of subjects: 30
Study 31247584 — intervention group
Group type: EXPERIMENTAL
Intervention: Random group (randomly shifted focus between visual and kinesthetic information)
Number of subjects: 30